Nevertheless, considering the acknowledged immunological functions of IL-36 and IL-37 in the context of HCC, as mentioned above, it is conceivable that the targeting of T cells through anti-PD-1/PD-L1 therapies could potentially influence the production of IL-36 and/or IL-37, thereby yielding downstream effects. The gene discussed is IL37; the disease is hepatocellular carcinoma.